RxDoctor Payments Data

Sandip Parikh, MD

Internal Medicine · Brick, NJNPI 1952347619

Payments from drug & device makers

$2,161in general payments, 2019–2025

Across 99 payments — averaging $21.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$361
  • Pfizer$254
  • E.r. Squibb & Sons, L.L.C.$235
  • Boston Scientific$194
  • Merck$190
  • AstraZeneca$137
  • plus $790 from 16 others

What the payments were for

  • Food & beverage$2,161100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,161 in reported general payments places this provider in the 75th percentile of 4,032 internal medicine providers in New Jersey.

See all internal medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$186,118
Medicare patients
166
Services billed
1,911

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban39$45,206
JardianceEmpagliflozin25$34,614
FarxigaDapagliflozin Propanediol26$32,127
JanuviaSitagliptin Phosphate18$26,809
XareltoRivaroxaban40$26,008
TradjentaLinagliptin18$18,690
OzempicSemaglutide13$16,256
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$12,216
Pitavastatin Calcium11$4,689
Atorvastatin Calcium255$2,759
Albuterol Sulfate HfaAlbuterol Sulfate43$1,913
Levothyroxine Sodium127$1,700
Losartan Potassium137$1,686
Metoprolol Succinate128$1,623
Ezetimibe44$1,564

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$135$53,30343 claims
PfizerEliquis$254$45,20639 claims
AstraZenecaFarxiga$137$32,12726 claims
MerckJanuvia$190$26,80918 claims
Johnson & JohnsonXarelto$361$26,00840 claims
Novo NordiskOzempic$16$16,25613 claims
GSKTrelegy Ellipta$47$12,21613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,032 internal medicine providers in New Jersey.

Other internal medicine in Brick

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →